Evidence map›Paper›PMID 41443420›Full record

ArticleThe Journal of biological chemistry2026

Nanobodies against Clostridioides difficile CDTb provide a toolkit for potent toxin neutralization and highly sensitive quantitation.

Kateryna Nabukhotna, Heather K Kroh, David M Anderson, Rubén Cano Rodríguez, John A Shupe, Maria McGresham, Carla V T O'Neale, Rebecca A Shrem, Brian E Wadzinski, Kevin L Schey and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kateryna NabukhotnaDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Heather K KrohDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
David M AndersonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Rubén Cano RodríguezDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
John A ShupeDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Maria McGreshamCarterra, Salt Lake City, Utah, USA.
Carla V T O'NealeDepartment of Biochemistry, Vanderbilt University, Nashville, Tennessee, USA.
Rebecca A ShremDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
Brian E WadzinskiDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
Kevin L ScheyDepartment of Biochemistry, Vanderbilt University, Nashville, Tennessee, USA.
Benjamin W SpillerDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA. Electronic address: benjamin.spiller@vanderbilt.edu.
D Borden LacyDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, USA; Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA. Electronic address: borden.lacy@vanderbilt.edu.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile VaccinesU19AI174999 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ivelin Georgiev · 2023 to 2026
$7.9M
Structural Mechanisms of Clostridioides difficile pathogenesisR37AI095755 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Dana Borden Lacy · 2021 to 2026
$3.2M
BLRD VA I01 BX002943NCI NIH HHS P30 CA068485NIAID NIH HHS R37 AI095755NIAID NIH HHS U19 AI174999NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

Clostridioides difficile is a pathogenic bacterium and a leading cause of antibiotic-associated diarrhea. Symptoms of the infection arise because of the production of large clostridial toxins that disrupt the intestinal barrier and cause an acute host inflammatory response. Epidemic C. difficile strains also produce the C. difficile transferase toxin (CDT), a binary toxin consisting of separate enzymatically active (CDTa) and cell-binding (CDTb) components. However, the role of CDT during C. difficile pathogenesis remains poorly understood. We created a CDTb nanobody (Nb) clone library and identified and purified five clones with promising CDTb-binding properties. Studies using the Carterra LSA

Indexed as

ADP Ribose TransferasesAntibodies, NeutralizingBacterial ProteinsBacterial ToxinsClostridioides difficileSingle-Domain AntibodiesAnimalsHumansMiceactin-specific ADP-ribosyltransferase, ClostridiumADP Ribose TransferasesAntibodies, NeutralizingBacterial ProteinsBacterial ToxinsSingle-Domain AntibodiesC. difficileepitope characterizationmolecular mechanismnanobodyprotein–protein interactionstoxin

Identifiers

PMID41443420
PMCPMC12828747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.